Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

20211,684 citationsJournal Articlebronze Open Access

Authors

Ronan J. Kelly · Inserm

Jaffer A. Ajani · The University of Texas MD Anderson Cancer Center

Jarosław Kużdżał · Jagiellonian University

Thomas Zander · Inserm

Eric Van Cutsem · Inserm

Guillaume Piessen · Inserm

Guillermo Méndez ·

Abstract

Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among those who received nivolumab adjuvant therapy than among those who received placebo. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 577 ClinicalTrials.gov number, NCT02743494.).

Topics & Keywords

Esophageal Cancer Research and Treatment Gastric Cancer Management and Outcomes Gastrointestinal Tumor Research and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 13, pp. 1191-1203

DOI: 10.1056/nejmoa2032125

Field-Weighted Citation Impact: 266.56